MedImmune, AstraZeneca’s global biologics research and development arm, has partnered with 4D Molecular Therapeutics (4DMT), a company specializing in gene-therapy vector discovery and product development, to develop and commercialize a gene therapeutic for patients with chronic lung disease, using 4DMT’s discovery platform to generate adeno associated virus (AAV) vectors.

AAV vectors are a delivery vehicle for transporting genes to accessible tissues in the body for in-vivo expression and therapeutic application. They target both dividing and nondividing cells without integrating genetic material into the host genome, according to information from the companies. The genetic material transferred by AAV vectors into cells is the blueprint for the production of a protein whose function targets pathological processes contributing to diseases.

The collaboration will use 4DMT’s experience in vector discovery and engineering, optimization, and process development. MedImmune will conduct product development beginning from early clinical stages.

Source: 4D Molecular Therapeutics